CD8A and ovarian cancer: Other investigators have shown that in ovarian cancer cells, the addition of panobinostat to olaparib enhanced the efficacy of olaparib by modulating the expression of genes involved in homologous recombination repair and immune response, and the combination reduced tumor growth and increased tumor cell death, DNA damage, and CD8+ T cell infiltration [38].